Reply to 'Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels' by Widmer et al. [2]

Leukemia

Volumn 21, Issue 7, 2007, Pages 1562-1563

  Zong, Y ^a,b   Zhou, S ^a   Sorrentino, B P ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA;

BINDING SITE; CANCER RESISTANCE; CELL LEVEL; CHRONIC MYELOID LEUKEMIA; DOWN REGULATION; DRUG RESPONSE; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE SILENCING; GENOTYPE; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

EID: 34250727018     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404672     Document Type: Letter

References (10)

1. Widmer N, Rumpold H, Untergasser G, Fayet A, Buclin T, Decosterd LA. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia (in press).
2. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085-1092.
3. Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003; 307: 824-828.
4. Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia 2005; 19 1590-1596.
5. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006; 80: 192-201.
6. Theou N, Gil S, Devocelle A, Julie C, Lavergne-Slove A, Beauchet A et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res 2005; 11: 7593-7598.
7. Zong Y, Zhou S, Sorrentino BP. Reply to Rumpold et al. Leukemia 2006; 20: 144-145.
8. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-2337.
9. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006; 108: 1370-1373.
10. Nakanishi T, Shiozawa K, Hassel BA, Ross DD. Complex interaction of BCRP/ ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 2006; 108: 678-684.